A correlative study from Memorial Sloan Kettering Cancer Center (MSKCC) also suggested that CDK4/6i does not offer any significant benefits to BRCA2 germline pathogenic variant carriers with metastatic BC (mBC) due to CDK4/6i resistance (38). Here, BRCA2 is linked to breast cancer.